Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular-Guided Surgery for Pancreatic and GI NETs
NCT03623984Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga 68 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by University of Alabama at Birmingham. Primary endpoint: Comparison of intraoperative findings to preoperative PET scan findings. Planned start Jun 2019; status: withdrawn.
02
Drugs
gallium ga 68 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03623984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623984.